Results 91 to 100 of about 773 (166)
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
, 2020 International audienceScleromyxedema is a rare skin and systemic mucinosis that is usually associated with monoclonal gammopathy (MG). In this French, multicenter, retrospective study of 33 patients, we investigated the clinical and therapeutic features ...
Sassolas, Bruno +45 more
core +1 more source
Immunochemical Analysis of the Monoclonal Paraprotein in Scleromyxedema
, 1978 The monoclonal paraprotein from a typical case of scleromyxedema was isolated and characterized. The isolated paraprotein was of the IgG-lambda class, with a molecular weight of approximately 110,000 daltons compared with 160,000 daltons for normal IgG ...
Miyagawa, Sachiko +7 more
core +1 more source
Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema
, 2020 Scleromyxedema or generalized lichen myxedematosus is a rare depositional disorder. Diagnostic criteria encompass a generalized papular and sclerodermoid eruption, monoclonal gammopathy (paraproteinemia), most often with G-lambda type immunoglobulin,
Špela Baglama +3 more
core
Scleromyxedema and inflammatory myopathy: A clinicopathology study of three patients
, 1986 Scleromyxedema (lichen myxedematosus is a rare cutaneous manifestation in patients with idiopathic inflammatory myopathy. The clinical and histological findings in three patients with this association are presented. Two patients had a severe inflammatory
Mastaglia, F.L. +4 more
core
Scleromyxedema problem in odontological practice
, 2019 Scleromyxedema is a skin disorder, which is considered very rare. Its symptoms are mucin accumulation in the patients’ skin, which is also called mucinosis. It causes papular and sclerodermoid bumps.
Gleiznys, Alvydas +1 more
core +1 more source
Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients.
, 2004 Scleromyxedema is a generalized, papular, and sclerodermoid form of lichen myxedematosus associated with monoclonal gammopathy and systemic changes.
GIROLOMONI, Giampiero +5 more
core
Plasmapheresis in a patient with scleromyxedema.
, 1987 We describe a patient with progressive scleromyxedema who failed to respond to previously described treatment modalities. A trial of plasmapheresis was initiated, but after an initial promising response, his disease continued to progress.
Lookingbill, D P, Westheim, A I
core
A case of generalized scleromyxedema that responded to IVIG monotherapy
, 2015 A 49-year-old African-American female presented with a mildly pruritic rash with an initial biopsy showing changes suggestive of interstitial granuloma annulare versus papular mucinosis.
Kannan, Swati, Kerr, Holly
core
Scleromyxedema: A potentially disabling and fatal disease
, 2000 Scleromyxedema (SCL), considered to be the generalized and sclerodermoid subtype of lichen myxedematosus (papular mucinosis), is a disease with a chronic, progressive, and potentially disabling course.
Rongioletti F.
core
Editorial: Innovative integrated immuno-and inflammopharmacology in reference to autoimmune skin diseases. [PDF]
Front Cell Dev Biol, 2023 Gabig-Cimińska M, Alves C.
europepmc +1 more source